Table 1

Baseline demographics and clinical, MRI and radiographic characteristics

TCZ+MTX (N=31)TCZ+PBO (N=32)
Demographics and clinical characteristics
Female, n (%)24 (77.4)21 (65.6)
 Age, mean (SD), year55.2 (14.12)55.8 (10.46)
 Disease duration, mean (SD), year7.8 (7.23)6.5 (8.07)
Disease duration, n (%)
 <2 years10 (32.3)13 (40.6)
 ≥2 to <5 years4 (12.9)7 (21.9)
 ≥5 to <10 years6 (19.4)4 (12.5)
 ≥10 years11 (35.5)8 (25.0)
 Oral steroids, n (%)15 (48.4)13 (40.6)
 No. of previous DMARDs, mean (SD)1.5 (1.18)1.5 (0.62)
 CRP, mean (SD), mg/dL1.1 (1.38)1.3 (1.88)
 DAS28, mean (SD)6.4 (1.0)6.5 (1.1)
MRI, n (%)
 Synovitis present, n (%)31 (100)32 (100)
 Osteitis present, n (%)22 (71)24 (75)
 Erosion present, n (%)31 (100)32 (100)
Modified RAMRIS, mean (SD)
 Synovitis7.23 (4.604)7.42 (4.164)
 Osteitis7.77 (12.261)11.06 (14.800)
 Erosion19.37 (14.440)15.97 (12.558)
X-ray, mean (SD)
 Total mTSS, mean (SD)21.23 (25.475)19.01 (24.988)
 Joint space narrowing, mean (SD)10.48 (13.701)7.94 (12.198)
 Erosion, mean (SD)10.76 (12.202)11.07 (13.993)
  • CRP, C-reactive protein; DAS28, Disease Activity Score of 28 joints; DMARDs, disease-modifying antirheumatic drugs; mTSS, Genant-modified Total Sharp Score; MTX, methotrexate; PBO, placebo; RAMRIS, rheumatoid arthritis MRI score; TCZ, tocilizumab.